Dr Paul D Abel

Publications


Journals

  • Karavitakis M; Ahmed HU; Abel PD; Livni N; Hazell S; Winkler MH. (10 Feb 2012). Trends in pathologic outcomes after introduction of active surveillance in the UK: Implication for focal therapy. Prostate. DOI.
  • Karavitakis M; Ahmed HU; Abel PD; Hazell S; Winkler MH. (May 2012). Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer. J Endourol. 26:503-508. DOI.
  • Karavitakis M; Winkler MH; Abel PD; Hazell S; Ahmed HU. (Sep 2011). Focal therapy for prostate cancer: opportunities and uncertainties. Discov Med. 12:245-255.
  • Monzon L; Wasan H; Leen E; Ahmed H; Dawson PM; Harvey C; Muhamed A; Hand J; et alPrice P; Abel PD. (Sep 2011). Transrectal high-intensity focused ultrasonography is feasible as a new therapeutic option for advanced recurrent rectal cancer: report on the first case worldwide. Ann R Coll Surg Engl. 93:e119-e121. DOI.
  • Langley RE; Cafferty FH; Pollock PA; Price P; Abel PD. (1 Jun 2011). Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. JOURNAL OF UROLOGY. 185:2430-2431. Author weblink.
  • Pillai R; Wang D; Mayer EK; Abel P. (2011). Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort. ScientificWorldJournal. 11:751-759. DOI.
  • Langley RE; Cafferty FH; Pollock PA; Price P; Abel PD. (Jun 2011). Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321. J Urol. 185:2430-2431. DOI.
  • Karavitakis M; Ahmed HU; Abel PD; Hazell S; Winkler MH. (1 Mar 2011). RELATIONSHIP OF RADICAL PROSTATECTOMY MARGIN STATUS AND INDEX LESION: IMPLICATIONS FOR PREOPERATIVE EVALUATION OF TUMOUR FOCALITY IN PROSTATE CANCER. EUROPEAN UROLOGY SUPPLEMENTS. 10:300-300. Author weblink.
  • Karavitakis M; Ahmed HU; Abel PD; Hazell S; Winkler MH. (1 Jan 2011). Tumor focality in prostate cancer: implications for focal therapy. NATURE REVIEWS CLINICAL ONCOLOGY. 8:48-55. Author weblink DOI.
  • Langley RE; Price P; Abel PD. (Apr 2011). Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91. Eur Urol. 59:e24-e25. DOI.
  • Gannon K; Guerro-Blanco M; Patel A; Abel P. (1 Dec 2010). Re-constructing masculinity following radical prostatectomy for prostate cancer. AGING MALE. 13:258-264. DOI.
  • Mahmalji W; Mukerji G; Abel P; Raza A. (Nov 2010). A community urology service: fact or fiction?. BJU Int. 106:1428-1430.
  • Romanska H; Salagierski M; Bruton R; Abel P; Sosnowski M; Lalani E. (2010). Doxazocin induces apoptosis in PTEN-positive androgen independent PC cells via inhibition of Akt activation. Central Journal of European Urology. 63:91-97.
  • Pope A; Abel P. (2010). Androgen Deprivation Therapy for Prostate Cancer and its Complications. Trends in Urology Gynaecology and Sexual Health. 15:32-37.
  • Langley R; Price P; Pollock P; Abel P. (2010). OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING BUT UNDER-RECOGNISED PROBLEM. British Journal Of Urology International. 106:726-727.
  • Karavitakis M; Winkler M; Abel P; Livni N; Beckley I; Ahmed HU. (Mar 2011). Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 14:46-52. DOI.
  • Abel PD. (Jan 2010). Osteoporosis in Patients with Prostate Cancer on Long-Term Androgen Deprivation. BMJ. Publisher weblink.
  • Ockrim J; Abel PD. (2009). Androgen deprivation therapy for prostate cancer – the potential of parenteral estrogen. Central European Journal of Urology. 62:132-140.
  • Low VJ; Wang D; Abel PD. (Jun 2010). Survival of patients with bladder cancer from a UK hospital: a 10-year follow-up study. BJU Int. 105:1667-1671. DOI.
  • Ockrim JL; Abel PD. (4 Oct 2008). Long term androgen deprivation therapy in prostate cancer. BRITISH MEDICAL JOURNAL. 337. Author weblink DOI.
  • Langley RE; Godsland IF; Kynaston H; Clarke NW; Rosen SD; Morgan RC; Pollock P; Kockelbergh R; et alLalani ELN; Dearnaley D; Parmar M; Abel PD. (Aug 2008). Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 102:442-445. DOI.
  • Norman G; Dean ME; Langley RE; Hodges ZC; Ritchie G; Parmar MKB; Sydes MR; Abel P; et alEastwood AJ. (19 Feb 2008). Parenteral oestrogen in the treatment of prostate cancer: a systematic review. BRITISH JOURNAL OF CANCER. 98:697-707. Author weblink DOI.
  • Wharton IP; Rivens IH; ter Haar GR; Gilderdale DJ; Collins DJ; Hand JW; Abel PD; deSouza NM. (1 Mar 2007). Design and development of a prototype endocavitary probe for high-intensity focused ultrasound delivery with integrated magnetic resonance imaging. JOURNAL OF MAGNETIC RESONANCE IMAGING. 25:548-556. Author weblink DOI.
  • Pillai R; Wang D; Abel P. (1 Mar 2007). Is the proposed EORTC prognostic algorithm for pTa/pT1 bladder transitional cell cancer (TCC) valid in a routine clinical setting?. EUROPEAN UROLOGY SUPPLEMENTS. 6:172-172. Author weblink DOI.
  • Ockrim J; Lalani ELN; Abel P. (Oct 2006). Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy. Nat Clin Pract Oncol. 3:552-563. DOI.
  • Ockrim JL; Lalani ELN; Aslam M; Standfield N; Abel PD. (Mar 2006). Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?. BJU Int. 97:498-504. DOI.
  • Guerro-Blanco M; Gannon K; Abel P. (1 Aug 2005). Loss of reproductive potential following surgical treatment for prostate cancer and constructions of masculinity. JOURNAL OF REPRODUCTIVE AND INFANT PSYCHOLOGY. 23:271-272. Author weblink.
  • Ockrim JL; Lalani ELN; Kakkar AK; Abel PD. (Aug 2005). Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol. 174:527-533.
  • Ockrim JL; Lalani EN; Abel PD. (1 May 2005). Re: Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy. JOURNAL OF UROLOGY. 173:1829-1829. Author weblink DOI.
  • Ockrim JL; Lalani EN; Banks LM; Svensson WE; Blomley MJ; Patel S; Laniado ME; Carter SS; et alAbel PD. (1 Dec 2004). Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. JOURNAL OF UROLOGY. 172:2203-2207. Author weblink DOI.
  • El Sheikh SS; Domin J; Abel P; Stamp G; Lalani ELN. (Nov 2004). Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia. 6:846-853. DOI.
  • Gannon K; Glover L; Abel P. (1 Sep 2004). Masculinity, infertility, stigma and media reports. SOCIAL SCIENCE & MEDICINE. 59:1169-1175. Author weblink DOI.
  • Siu LS; Romanska H; Abel PD; Kayademir T; Blin N; Stamp GW; Lalani ELN. (May 2004). TFF1 is membrane-associated in breast carcinoma cell line MCF-7. Peptides. 25:745-753. DOI.
  • Siu LS; Romanska H; Abel PD; Baus-Loncar M; Kayademir T; Stamp GW; Lalani ELN. (May 2004). TFF2 (trefoil family factor2) inhibits apoptosis in breast and colorectal cancer cell lines. Peptides. 25:855-863. DOI.
  • Khan AA; Abel PD; Chaudhary KS; Gulzar Z; Stamp GW; Lalani EN. (Dec 2003). Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder. Mol Pathol. 56:353-361.
  • El Sheikh SS; Domin J; Tomtitchong P; Abel P; Stamp G; Lalani EN. (16 Oct 2003). Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin Pathol. 3:4. DOI.
  • Nightingale J; Chaudhary KS; Abel PD; Stubbs AP; Romanska HM; Mitchell SE; Stamp GW; Lalani ELN. (Jul 2003). Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia. 5:347-361.
  • Ockrim JL; Lalani EN; Laniado ME; Carter SS; Abel PD. (May 2003). Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J Urol. 169:1735-1737. DOI.
  • El Sheikh SS; Domin J; Abel P; Stamp G; Lalani ELN. (Mar 2003). Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia. 5:99-109.
  • deSouza NM; Daniels OJ; Williams AD; Gilderdale DJ; Abel PD. (Nov 2002). Female urinary genuine stress incontinence: anatomic considerations at MR imaging of the paravaginal fascia and urethra initial observations. Radiology. 225:433-439.
  • El Sheikh SS; Madaan S; Alhasso A; Abel P; Stamp G; Lalani EN. (1 May 2002). Cyclo-oxygenase 2: a possible target in schistosome-associated bladder cancer. BRITISH JOURNAL OF SURGERY. 89:664-664. Author weblink.
  • Ockrim JL; Lalani EN; Laniado ME; Carter SS; Abel PD. (1 May 2002). Transdermal oestrogen therapy for advanced prostate cancer. BRITISH JOURNAL OF SURGERY. 89:634-634. Author weblink.
  • Mitchell S; Abel P; Madaan S; Jeffs J; Chaudhary K; Stamp G; Lalani ELN. (Jan 2002). Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia. 4:9-18.
  • Kraus S; Abel PD; Nachtmann C; Linsenmann HJ; Weidner W; Stamp GW; Chaudhary KS; Mitchell SE; et alFranke FE; Lalani ELN. (Jan 2002). MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol. 33:60-67.
  • El-Sheikh SS; Madaan S; Alhasso A; Abel P; Stamp G; Lalani EN. (Dec 2001). Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer. BJU Int. 88:921-927.
  • Moledina J; ElSheikh SS; Abel P; Stamp G; Lalani EN. (1 Sep 2001). iNOS expression is not regulated by ligand activation of the androgen receptor or bcl-2 in a prostate cancer cell line model. JOURNAL OF PATHOLOGY. 195:15A-15A. Author weblink.
  • Gannon K; Glover L; Bevin C; McWilliams B; Brown E; Abel P. (1 Aug 2001). Sperm counts, media reports and social constructions of masculinity. JOURNAL OF REPRODUCTIVE AND INFANT PSYCHOLOGY. 19:265-265. Author weblink.
  • Madaan S; Abel PD. (1 Aug 2001). Urethral metastasis after transurethral resection of a malignant prostate. BJU INTERNATIONAL. 88:308-308. Author weblink DOI.
  • Hudson MJ; Stamp GW; Chaudhary KS; Hewitt R; Stubbs AP; Abel PD; Lalani EN. (Jul 2001). Human MUC1 mucin: a potent glandular morphogen. J Pathol. 194:373-383. DOI.
  • Chaudhary KS; Abel PD; Stamp GW; Lalani E. (Apr 2001). Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol. 193:522-529. DOI.
  • Madaan S; Abel PD; Chaudhary KS; Hewitt R; Stott MA; Stamp GW; Lalani EN. (Oct 2000). Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86:736-741.
  • Hodgson DJ; Mitchell SE; Abel PD; Lalani EN. (1 Sep 2000). Immunocytochemical detection of E-cadherin - towards a standardised protocol for antigen retrieval. JOURNAL OF PATHOLOGY. 192:6A-6A. Author weblink.
  • Khan AA; Chaudhary KS; Abel PD; Stamp GWH; Lalani EN. (1 Sep 2000). Inverse correlation between high-level expression of Cyclin E and proliferation index in transitional cell carcinoma of the bladder. JOURNAL OF PATHOLOGY. 192:25A-25A. Author weblink.
  • Alhasso A; Madaan S; Abel PD; El Baz M; Stamp GWH; Lalani EN. (1 Sep 2000). Over-expression of cyclooxygenase-2 in schistosomiasis associated bladder cancer. JOURNAL OF PATHOLOGY. 192:8A-8A. Author weblink.
  • Khan AA; Chaudhary KS; Abel PD; Shoma AM; El Baz M; Stamp GWH; Lalani EN. (1 Jul 2000). Expression of cyclin D1, cyclin E and p27(KIP1) in schistosomal versus nonschistosomal bladder cancer. BRITISH JOURNAL OF CANCER. 83:59-59. Author weblink.
  • Mitchell S; Abel P; Ware M; Stamp G; Lalani E. (May 2000). Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 85:932-944.
  • Nightingale J; Chaudhary KS; Abel PD; Stamp GWH; Lalani EN. (1 Mar 2000). Androgen dependent down regulation of E-cadherin expression in an in vitro model of prostate cancer. JOURNAL OF PATHOLOGY. 190:30A-30A. Author weblink.
  • Mitchell SE; Abel PD; Stamp GWH; Lalani E. (1 Mar 2000). Androgen dependent up-regulation of MUC1 in an in vitro model of prostate cancer. JOURNAL OF PATHOLOGY. 190:43A-43A. Author weblink.
  • Chaudhary KS; Abel PD; Nightingale J; Stamp GWH; Lalani EN. (1 Mar 2000). Bcl-2 expression confers an androgen refractory phenotype to androgen receptor expressing prostatic cancer cells. JOURNAL OF PATHOLOGY. 190:30A-30A. Author weblink.
  • Madaan S; Abel PD; Chaudhary KS; Stamp GWH; Lalani EN. (1 Mar 2000). Over-expression of COX-2 in human prostate cancer. JOURNAL OF PATHOLOGY. 190:44A-44A. Author weblink.
  • Lu QL; Abel P; Mitchell S; Foster C; Lalani EN. (Feb 2000). Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases. J Pathol. 190:169-176. DOI.
  • Glover L; Hunter M; Richards JM; Katz M; Abel PD. (Oct 1999). Development of the fertility adjustment scale. Fertil Steril. 72:623-628.
  • Stamp GWH; Abel PD; Lalani EN. (1 Sep 1999). Androgen regulated gene expression in prostate cancer. EUROPEAN JOURNAL OF CANCER. 35:S384-S385. Author weblink DOI.
  • Stubbs AP; Abel PD; Golding M; Bhangal G; Wang Q; Waxman J; Stamp GW; Lalani EN. (May 1999). Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol. 154:1335-1343. DOI.
  • Chaudhary KS; Abel PD; Nightingale J; Stamp GW; Lalani EN. (12 Mar 1999). Bcl-2 inhibits ligand mediated nuclear translocation of androgen receptor in prostatic cancer cells. FASEB JOURNAL. 13:A195-A195. Author weblink.
  • Nightingale J; Chaudhary KS; Abel PD; Stamp GW; Lalani EN. (12 Mar 1999). E-Cadherin expression is regulated by the androgen receptor in prostate cancer cell lines. FASEB JOURNAL. 13:A195-A195. Author weblink.
  • Stubbs AP; Abel PD; Golding M; Williamson G; Bangal G; Stamp GWH; Lalani EN. (12 Mar 1999). Over expression of fibronectin in hormone-insensitive prostate cancer cells. FASEB JOURNAL. 13:A342-A342. Author weblink.
  • Glover L; Gannon K; Platt Z; Abel PD. (1 Feb 1999). Male subfertility clinic attenders' expectations of medical consultation. BRITISH JOURNAL OF HEALTH PSYCHOLOGY. 4:53-61. Author weblink DOI.
  • Chaudhary KS; Abel PD; Lalani EN. (Feb 1999). Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect. 107 Suppl 1:49-57.
  • Wang Q; Stamp GW; Powell S; Abel P; Laniado M; Mahony C; Lalani EN; Waxman J. (Jan 1999). Correlation between androgen receptor expression and FGF8 mRNA levels in patients with prostate cancer and benign prostatic hypertrophy. J Clin Pathol. 52:29-34.
  • Laniado ME; Abel PD; Lalani EN. (4 Jul 1998). Ion channels - reply. BRITISH MEDICAL JOURNAL. 317:77-77. Author weblink.
  • Black NA; Bowling A; Griffiths JM; Pope C; Abel PD. (Jun 1998). Impact of surgery for stress incontinence on the social lives of women. Br J Obstet Gynaecol. 105:605-612.
  • Glover L; Abel PD; Gannon K. (9 May 1998). Male subfertility: Is pregnancy the only issue? Psychological responses matter too - and are different in men. BRITISH MEDICAL JOURNAL. 316:1405-1406. Author weblink.
  • Bower M; Ma R; Savage P; Abel P; Waxman J. (Apr 1998). British urological surgery practice: 2. Renal, bladder and testis cancer. Br J Urol. 81:513-517.
  • Griffiths JM; Black NA; Pope C; Stanley J; Bowling A; Abel PD. (1998). What determines the choice of procedure in stress incontinence surgery? The use of multilevel modeling. Int J Technol Assess Health Care. 14:431-445.
  • Black N; Griffiths J; Pope C; Bowling A; Abel P. (6 Dec 1997). Impact of surgery for stress incontinence on morbidity: cohort study. BMJ. 315:1493-1498.
  • Laniado ME; Abel PD; Lalani EN. (8 Nov 1997). Ion channels. BRITISH MEDICAL JOURNAL. 315:1171-1172. Author weblink.
  • Gavrilov LR; Hand JW; Abel P; Cain CA. (1 Sep 1997). A method of reducing grating lobes associated with an ultrasound linear phase array intended for transrectal thermotherapy. IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL. 44:1010-1017. Author weblink DOI.
  • Geroulakos G; Abel P. (21 Jun 1997). Effect of renal-artery stenting on progression of renovascular renal failure. LANCET. 349:1840-1840. DOI.
  • Lalani el-N; Laniado ME; Abel PD. (Jun 1997). Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev. 16:29-66.
  • Savage P; Bates C; Abel P; Waxman J. (May 1997). British urological surgery practice: 1. Prostate cancer. Br J Urol. 79:749-754.
  • Laniado ME; Lalani EN; Fraser SP; Grimes JA; Bhangal G; Djamgoz MBA; Abel PD. (1 Apr 1997). Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. AMERICAN JOURNAL OF PATHOLOGY. 150:1213-1221. Author weblink.
  • Lu QL; Laniado M; Abel PD; Stamp GW; Lalani EN. (Feb 1997). Expression of bcl-2 in bladder neoplasms is a cell lineage associated and p53-independent event. Mol Pathol. 50:28-33.
  • Chaudhary KS; Lu QL; Abel PD; Khandan-Nia N; Shoma AM; el Baz M; Stamp GW; Lalani EN. (Jan 1997). Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder. Br J Urol. 79:78-84.
  • Wang O; Lalani EN; Powell S; Waxman J; Abel P; Jackson D; Stamp GWH. (1 Jan 1997). FGF8 mRNA expression in benign and malignant prostate - Relationship to androgen receptor status. JOURNAL OF PATHOLOGY. 181:A35-A35. Author weblink.
  • Lu QL; Lalani el-N; Abel P. (1997). Human papillomavirus 16 and 18 infection is absent in urinary bladder carcinomas. Eur Urol. 31:428-432.
  • Nightingale J; Koumarinou A; Waxman J; Abel PD; Lalani EN; Stamp GWH. (1 Jan 1997). Integrin profiles of prostatic carcinomas and prostatic cell lines. JOURNAL OF PATHOLOGY. 181:A51-A51. Author weblink.
  • Ware MA; Stubbs AP; Bhangal G; Waxman J; Abel PD; Stamp GWH; Lalani EN. (1 Jan 1997). Sequence analysis of the androgen receptor exon 1 CAG trinucleotide repeats in several cell lines (prostatic and non-prostatic) and in microdissected prostatic adenocarcinomas. JOURNAL OF PATHOLOGY. 181:A35-A35. Author weblink.
  • Hines J; Laniado M; Thompson J; Sellu D; Abel P. (Dec 1996). Unusual presentations of pericolic abscess following nephrectomy. Br J Urol. 78:955-956.
  • Leung HY; Cooper S; Razack AH; Falzon M; Abel PD. (Dec 1996). Ureteric filling defect. Postgrad Med J. 72:759-760.
  • Glover L; Gannon K; Sherr L; Abel PD. (1 Nov 1996). Differences between doctor and patient estimates of outcome in male sub-fertility clinic attenders. BRITISH JOURNAL OF CLINICAL PSYCHOLOGY. 35:531-542. Author weblink.
  • Danziger R; Abel P; Goddard N; McGrouther DA; Pawson ME. (12 Oct 1996). Preoperative testing for HIV: A survey of surgeons' attitudes and practices. LANCET. 348:1036-1037. Author weblink DOI.
  • Stubbs AP; Lalani EN; Stampa GWH; Hurst H; Abel P; Waxman J. (22 Jul 1996). Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145 (vol 383, pg 237, 1996). FEBS LETTERS. 390:240-240. Author weblink DOI.
  • Crinnion JN; Marino A; Grace PA; Abel P. (May 1996). Compartment syndrome: a very rare but potentially lethal complication of prolonged pelvic surgery. Br J Urol. 77:750-751.
  • Stubbs AP; Lalani EN; Stamp GW; Hurst H; Abel P; Waxman J. (1 Apr 1996). Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145. FEBS Lett. 383:237-240.
  • Badia JM; Whawell SA; ScottCoombes DM; Abel PD; Williamson RCN; Thompson JN. (1 Mar 1996). Peritoneal and systemic cytokine response to laparotomy. BRITISH JOURNAL OF SURGERY. 83:347-348. Author weblink DOI.
  • Lu QL; Abel P; Foster CS; Lalani EN. (Feb 1996). bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 27:102-110.
  • Grimes JA; Fraser SP; Stephens GJ; Downing JE; Laniado ME; Foster CS; Abel PD; Djamgoz MB. (7 Aug 1995). Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett. 369:290-294.
  • Sharpe JC; Abel PD; Gilbertson JA; Brawn P; Foster CS. (Nov 1994). Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol. 74:609-616.
  • BRAWN PN; JOHNSON EH; SPEIGHTS VO; RIGGS M; KUHL D; ABEL PD; LIND M; BELL N. (1 Sep 1994). INCIDENCE, RACIAL-DIFFERENCES, AND PROGNOSTIC-SIGNIFICANCE OF PROSTATE CARCINOMAS DIAGNOSED WITH OBSTRUCTIVE SYMPTOMS. CANCER. 74:1607-1611. Author weblink DOI.
  • Glover L; Gannon K; Sherr L; Abel PD. (Aug 1994). Psychological distress before and immediately after attendance at a male sub-fertility clinic. J R Soc Med. 87:448-449.
  • Bashir I; Sikora K; Abel P; Foster CS. (1 Jun 1994). Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer. 57:719-726.
  • DAGNELIE PC; BELL JD; WILLIAMS SCR; BATES TE; ABEL PD; FOSTER CS. (1 Mar 1994). EFFECT OF FISH-OIL ON CANCER CACHEXIA AND HOST LIVER-METABOLISM IN RATS WITH PROSTATE TUMORS. LIPIDS. 29:195-203. Author weblink DOI.
  • ABEL PD. (1 Mar 1994). FOLLOW-UP OF PATIENTS WITH SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE BLADDER - REPLY. BRITISH JOURNAL OF UROLOGY. 73:333-334. Author weblink.
  • DAVIES B; WAXMAN J; WASAN H; ABEL P; WILLIAMS G; KRAUSZ T; NEAL D; THOMAS D; et alHANBY A; BALKWILL F. (15 Nov 1993). LEVELS OF MATRIX METALLOPROTEASES IN BLADDER-CANCER CORRELATE WITH TUMOR GRADE AND INVASION. CANCER RESEARCH. 53:5365-5369. Author weblink.
  • Abel PD; Lindsay KS; Lord RH; MacGregor S; Floyd I; Williams G; Pusey CD. (Nov 1993). Effects of plasma exchange on sperm antibody levels in males with subfertility. Br J Urol. 72:820-821.
  • Abel PD. (Aug 1993). Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol. 72:135-142.
  • McLoughlin J; Foster CS; Price P; Williams G; Abel PD. (Jul 1993). Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol. 72:92-97.
  • Zafar F; Thompson JN; Pati J; Kiely EA; Abel PD. (Jul 1993). Sutureless circumcision. Br J Surg. 80:859.
  • DAGNELIE PC; BELL JD; WILLIAMS SCR; BATES TE; ABEL PD; FOSTER CS. (1 Jun 1993). ALTERED PHOSPHORYLATION STATUS, PHOSPHOLIPID-METABOLISM AND GLUCONEOGENESIS IN THE HOST LIVER OF RATS WITH PROSTATE-CANCER - A P-31 MAGNETIC-RESONANCE SPECTROSCOPY STUDY. BRITISH JOURNAL OF CANCER. 67:1303-1309. Author weblink DOI.
  • ABEL PD. (29 May 1993). SUPERFICIAL BLADDER-CANCER. BRITISH MEDICAL JOURNAL. 306:1480-1480. Author weblink.
  • Foster CS; Abel PD. (Apr 1992). Clinical and molecular techniques for diagnosis and monitoring of prostatic cancer. Hum Pathol. 23:395-401.
  • Foster CS; McLoughlin J; Bashir I; Abel PD. (Apr 1992). Markers of the metastatic phenotype in prostate cancer. Hum Pathol. 23:381-394.
  • Waxman J; Barton C; Biruls R; James N; Harrison M; Rogers H; Mee D; Sikora K; et alColbeck R; Abel P. (Feb 1992). Bladder cancer: inter-relationships between chemotherapy and radiotherapy. Br J Urol. 69:151-155.
  • THORPE SJ; ABEL P. (1 Apr 1991). DETECTION OF BLOOD GROUP-A AND H-RELATED ANTIGENS IN NORMAL AND NEOPLASTIC BLADDER EPITHELIUM - A COMPARATIVE-STUDY USING MONOCLONAL-ANTIBODIES WITH DEFINED FINE SPECIFICITIES. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY. 72:129-138. Author weblink.
  • MCLOUGHLIN J; BRAWN P; ABEL PD; WILLIAMS G; FOSTER CS. (1 Feb 1991). LECTIN-BINDING PATTERNS OF PRIMARY PROSTATIC CANCERS AND THEIR CORRESPONDING LYMPH-NODE METASTASES. JOURNAL OF PATHOLOGY. 163:A157-A157. Author weblink.
  • Abel PD; Foster CS; Tebbutt S; Williams G. (Sep 1990). Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. J Urol. 144:760-765.
  • QAYUM A; GULLICK W; ABEL P; WILLIAMS G; MELON K; NEAL D; SIKORA K; WAXMAN J. (1 Sep 1990). DIRECT EFFECTS OF GNRH ANALOGS IN PROSTATIC-CANCER. BRITISH JOURNAL OF CANCER. 62:531-531. Author weblink.
  • McLoughlin J; Gill KP; Abel PD; Williams G. (Sep 1990). Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy. Br J Urol. 66:303-305.
  • McLoughlin J; Jager R; Abel PD; el Din A; Adam A; Williams G. (Jul 1990). The use of prostatic stents in patients with urinary retention who are unfit for surgery. An interim report. Br J Urol. 66:66-70.
  • McLoughlin J; Abel PD; Shaikh N; Waters J; Williams G. (Jul 1990). Visual analogue scales distinguish between low urinary flow rates due to impaired detrusor contractility and those due to bladder outflow obstruction. Br J Urol. 66:16-18.
  • Williams G; Asopa R; Abel PD; Smith C. (May 1990). Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol. 65:504-508.
  • Abel PD; McCormack TT. (Apr 1990). Complicated peptic ulceration in a child. Br J Clin Pract. 44:159-160.
  • Abel PD; Foster CS; Tebbutt S; Williams G. (1990). A study of oligosaccharide determinants expressed by prostatic glandular epithelium of the normal adult rat. Urol Res. 18:233-237.
  • Waxman J; Sandow J; Abel P; Barton C; Keane P; Williams G. (Jan 1990). Three-monthly GnRH agonist (buserelin) for prostatic cancer. Br J Urol. 65:43-45.
  • MCLOUGHLIN J; ABEL PD. (20 May 1989). GRADING OF CERVICAL INTRAEPITHELIAL NEOPLASIA. BRITISH MEDICAL JOURNAL. 298:1383-1383. Author weblink.
  • Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; et alWilliams G. (Mar 1989). Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol (Copenh). 120:315-318.
  • Abel PD; Thorpe SJ; Williams G. (Feb 1989). Blood group antigen expression in frozen sections of presenting bladder cancer: 3-year prospective follow-up of prognostic value. Br J Urol. 63:171-175.
  • Abel PD; Keane P; Leathem A; Tebbutt S; Williams G. (Feb 1989). Change in glycoconjugate for the binding site of the lectin Ulex europeus 1 following malignant transformation of prostatic epithelium. Br J Urol. 63:183-185.
  • Waxman J; Abel P; James N; Farah N; O'Donoghue EP; Mee D; Colbeck R; Sikora K; et alWilliams G. (Jan 1989). New combination chemotherapy programme for bladder cancer. Br J Urol. 63:68-71.
  • Abel PD; Henderson D; Bennett MK; Hall RR; Williams G. (Oct 1988). Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol. 62:339-342.
  • Abel PD; Hall RR; Williams G. (Sep 1988). Should pT1 transitional cell cancers of the bladder still be classified as superficial?. Br J Urol. 62:235-239.
  • Cutner A; Abel PD. (Sep 1988). Undescended testis: a dual lesson. Br J Urol. 62:273-274.
  • Abel PD. (Aug 1988). Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol. 62:103-109.
  • ABEL PD. (1 Jul 1988). THE CORRELATION BETWEEN GROSS APPEARANCE OF THE APPENDIX AT APPENDECTOMY AND HISTOLOGICAL EXAMINATION. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND. 70:262-262. Author weblink.
  • WAXMAN J; WILLIAMS G; SANDOW J; HEWITT G; ABEL P; FARAH N; FLEMING J; COX J; et alODONOGHUE EPN; SIKORA K. (1 Jan 1988). THE CLINICAL AND ENDOCRINE ASSESSMENT OF 3 DIFFERENT ANTIANDROGEN REGIMENS COMBINED WITH A VERY LONG-ACTING GONADOTROPIN-RELEASING HORMONE ANALOG. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 11:S152-S155. Author weblink.
  • Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; et alO'Donoghue EP; Sikora K. (1988). The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol. 11 Suppl 2:S152-S155.
  • WAXMAN JH; WILLIAMS G; ABEL P; FARAH N; TIMMONY A; HEWITT G; ODONOGHUE EPN. (1 Aug 1987). THE PHARMACOLOGICAL AND ENDOCRINE ASSESSMENT OF 3 DIFFERENT ANTIANDROGEN REGIMENS COMBINED WITH A VERY LONG-ACTING GONADROTROPIN RELEASING HORMONAL ANALOG. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY. 23:1251-1251. Author weblink DOI.
  • ABEL PD; LEATHEM A; AYLOTT A; MARSH C; HENDERSON D; WILLIAMS G. (1 Jun 1987). CARBOHYDRATE RESIDUES IN NONMALIGNANT PROSTATIC EPITHELIUM AS REVEALED BY LECTINS. UROLOGICAL RESEARCH. 15:173-176. Author weblink.
  • ABEL PD; CORNELL C; BUAMAH PK; WILLIAMS G. (1 May 1987). ASSESSMENT OF SERUM CA 19.9 AS A TUMOR-MARKER IN PATIENTS WITH CARCINOMA OF THE BLADDER AND PROSTATE. BRITISH JOURNAL OF UROLOGY. 59:427-429. Author weblink DOI.
  • ABEL PD; MARSH C; HENDERSON D; LEATHEM A; POWELL PH; WILLIAMS G. (1 May 1987). DETECTION OF BLOOD-GROUP ANTIGENS IN FROZEN-SECTIONS OF PROSTATIC EPITHELIUM. BRITISH JOURNAL OF UROLOGY. 59:430-435. Author weblink DOI.
  • Abel PD; Williams G. (Feb 1987). Metastatic teratoma from a regressed impalpable testicular primary. Postgrad Med J. 63:143-144.
  • Thorpe SJ; Abel P; Henderson D; Jones N; Feizi T. (Nov 1986). Expression of blood group antigens in urinary tract tumours: prospective fluorescence study using cryostat sections of fresh frozen tissues. J Clin Pathol. 39:1165-1176.
  • ABEL P; LEATHEM A; AYOTT A; WILLIAMS G. (1 Jan 1986). THE USE OF LECTINS TO DEMONSTRATE MORPHOLOGICALLY IDENTICAL BENIGN PROSTATIC CELLS AND CHANGES IN CARBOHYDRATE EXPRESSION IN MALIGNANCY. UROLOGICAL RESEARCH. 14:167-167. Author weblink.
  • Neal DE; Marsh C; Bennett MK; Abel PD; Hall RR; Sainsbury JR; Harris AL. (16 Feb 1985). Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1:366-368.
  • McCormack TT; Collier JA; Abel PD; Collins CD; Ritchie WN. (May 1984). Attitudes to follow-up after uncomplicated surgery--hospital out-patients or general practitioner?. Health Trends. 16:46-47.
  • McCormack TT; Abel PD; Collins CD. (Sep 1983). Abdominal drainage following cholecystectomy: high, low, or no suction?. Ann R Coll Surg Engl. 65:326-328.
  • THORPE SJ; ABEL P; SLAVIN G; TENFEIZI. (1 Jan 1983). BLOOD-GROUP ANTIGENS IN THE NORMAL AND NEOPLASTIC BLADDER EPITHELIUM. JOURNAL OF CLINICAL PATHOLOGY. 36:873-882. Author weblink DOI.

Books

  • Abel PD. Abel PD (ed); Lalani E (ed). Prostate Cancer. Clinical and Scientific Aspects - Bridging the Gap. 1-1237. Imperial College Press, 57 Shelton Street, LONDON, WC2H 9HE (2003).

Conferences

  • Mukerji GM; Nariculam J; Hellawell GO; Abel P; Winkler M. Outcome of patients on active surveillance for low-risk prostate cancer in a cohort of British men with low screening penetrance. Annual Meeting of the British-Association-of-Urological-Surgeons, 21 Jun 2010 - 24 Jun 2010. 106:3-3. WILEY-BLACKWELL PUBLISHING, INC (1 Jan 2010). Author weblink.
  • Salagierski M; Romanska HM; Bruton R; Gulzar Z; Abel P; Sosnowski M; Lalani EN. DHT rescues prostate cancer cells from Doxazocin induced apoptosis. Joint Meeting of the European-Society-for-Urological-Research/Society-for-Basic-Urologic-Research - 7th World Basic Urological Research Congress. 100:37-37. (Sep 2007).
  • Langley R; Norman G; Dean ME; Hodges Z; Ritchie G; Light K; Sydes M; Parmar M; et alAbel P; Eastwood A. A systematic review of the safety and efficacy of parenteral estrogens in prostate cancer. 41st Annual Meeting of the American-Society-of-Clinical-Oncology. 23:421S-421S. (1 Jun 2005).

Patents

  • Estrogens for Prostate Cancer. Patent number: US 2004/0101549 A1 (USA). Application: 10/302,801. Filed: 27 May 2004.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook